In vitro and in vivo properties of CD133 expressing cells from human lung cancer cell lines by Wang, Ping et al.
RESEARCH Open Access
In vitro and in vivo properties of CD133 expressing
cells from human lung cancer cell lines
Ping Wang1,2,5,6, Zhenhe Suo3,5, Mengyu Wang1, Hanne K Høifødt4, Øystein Fodstad4,5, Gustav Gaudernack2,5
and Gunnar Kvalheim1,5*
Abstract
Background: Tumor development is recently hypothesized to depend on a rare cell population with stem cell
properties, such cells are called cancer stem cells (CSCs) or tumor-initiating cells (TICs). From various cancer tissues
or cancer cell lines, CD133 expressing cells were found to define a unique CSC/TIC phenotype. To study whether
that also could be the case in lung cancer, we examined different lung cancer cell lines for CD133 expression.
Results: Among the 4 cell lines studied, only the cell line LC-42 expressed CD133. Therefore, LC-42 was further
characterized and studied with special emphasis on identifying the presence of CD133+ CSCs/TICs. FACS sorted
CD133high and CD133dim subpopulations from LC-42 showed no differences in soft agar colony-forming capacity
and spheres-forming capacity in serum-free cultures. LC-42 cells contained Side Population (SP), and only SP cells
were able to form spheres. Furthermore, Nanog expression was significantly higher in SP than in non-SP. However,
no difference was observed of CD133 expression in SP and non-SP. When CD133high and CD133dim cells were
serially xeno-transplanted in NOD/SCID mice, both formed tumours similar to their parental LC-42 cells. There were
no expression differences for NANOG, OCT4 and SOX2 examined immunohistochemically in the xenografts from
both cell fractions.
Conclusion: Our data do not show a difference in tumorigenic potential of CD133high and CD133dim cells with
respect to any of the parameters analyzed in vitro and in vivo, suggesting that CD133 expression is not restricted to
cancer-initiating cells in the human lung cancer cell line LC-42.
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Introduction
Lung cancer is the number one cause of cancer-related
deaths by far in the western countries, even more fre-
quently seen than breast, prostate, and colon cancer
combined. Late appearance of clinical symptoms from a
lung cancer is the main reason for that the majority of the
patients have advanced disease at diagnoses. In Norway,
only 7% of the lung cancers are candidate for radical sur-
gery. New chemotherapy combinations and improved
radiotherapy methods have not improved the prognosis of
the lung cancer patients and the 5 year events-free sur-
vival is still <15% [1].
Traditional cancer treatments against lung cancer have
been developed based on targeting proliferating tumor
cells, but this therapy is proven ineffective since recur-
rence of the disease occurs often when the therapy is
stopped. Tumor growth is recently hypothesized to de-
pend on a rare cell population within a tumor propagat-
ing in vivo, and these cells are responsible for radio/
chemotherapy resistance and are the cause of recurrence
and metastasis after therapy. These cells, denominated
cancer stem cells (CSCs) or tumor-initiating cells (TICs),
is believed to share similar functions as its normal stem
cell counterparts [2,3], and can therefore be defined by
their self- renewal capacity and ability to differentiate.
Furthermore, they can be identified by stem cell associated
antigen expression and be sorted with a fluorescence-
activated cell sorter (FACS) for further molecular and bio-
logical studies. CSCs/TICs were first identified in human
leukemia using different cell surface markers and cell
* Correspondence: gunnar.kvalheim@medisin.uio.no
1Department of Cellular Therapy, Oslo University Hospital, Radiumhospitalet,
Oslo, Norway
5Faculty of Medicine, University of Oslo, Oslo, Norway
Full list of author information is available at the end of the article
Experimental 
Hematology & Oncology
© 2013 Wang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Wang et al. Experimental Hematology & Oncology 2013, 2:16
http://www.ehoonline.org/content/2/1/16
sorting. A subpopulation of acute myeloid leukemia cells
expressing the antigens CD34+CD38- assembled charac-
teristics and properties as stem cell, both in vitro and in
immunodeficient mice [4,5]. Since then, several groups
have identified other surface markers being associated
with CSC/TIC in solid tumors like breast cancer [6], brain
tumor [7], melanoma [8], colon cancer [9,10], pancreatic
cancer [11,12], prostate cancer [13] and head and neck
squamous cell carcinoma [14].
Normal lung tissue is composed of different types of
cells, basal mucous secretary cells in the trachea and
bronchi, Clara cells in the bronchioles and type 1 and
type 2 pneumocytes in the alveoli. These mature cells
derive from the differentiation of lineage-restricted lung
progenitor cells, which originate from undifferentiated
multipotent lung stem cells. Multipotent lung stem cells
have been identified throughout the airways and are
thought to be responsible for local tissue maintenance
and tissue repair. In 2005, Kim CF et al. became the first
one to identify bronchialveolar stem cells (BASCs) local-
ized at the bronchioalveolar duct junction. These puta-
tive stem cells formed the bronchiolar Clara cells and
alveolar cells of the distal lung. Interestingly, the same
investigators also found, in a mouse model, that tumor
initiating cells of lung adenocarcinoma originated from
malignant BASCs [15]. Human multipotent lung stem
cells and CSCs that give rise to all subtypes of lung can-
cers remain to be finally defined.
CD133 is a surface protein with five transmembrane
domains and was initially recognized as an antigen ex-
pressed on human stem and progenitor haematopoietic
cells [16]. Soon after that, the antibody CD133 was used
to isolate endothelial progenitor cells [17] and central
nervous system stem cells [18]. Low numbers of CD133+
cells were found in most adult human organs using the
original CD133 antibody (AC133) suggesting that this
antigen can be defined as an organ specific stem cell
marker. To date, CD133 antigen expression itself or
combined with other markers has been used to identify
and isolate tumor cells with stem cell characteristics in
brain tumor [7], colon cancer [9,10], prostate cancer
[13], pancreatic cancer [11], melanoma [19] and lung
cancer [20]. When sorted CD133+ tumor cells from
these types of tumors were tested in immunodeficient
mice, they showed unique ability to propagate tumors.
Despite the fact that CD133 antigen expression can be
used to identify and purify CSC population in some types
of solid tumors, recently, several groups have challenged
the idea that CD133 antigen expression can be used as a
general tumor stem cell marker. In colon cancer, CSCs are
not uniquely CD133+ since CD133- cells of the tumors
were able to produce CD133+ cells as well [21,22].
In this paper, we have used 4 different human lung
cancer cell lines to study subpopulations of cells with
CSC characteristics. Among the 4 human lung cancer cell
lines, the LC-42, which was established from a lymph node
metastasis of a squamous cell lung cancer, expressed the
CD133 antigen while the other cell lines were only weakly
or negative for CD133 expression. To investigate the prop-
erties of LC-42 cells in relation to the CD133 antigen
expression, different in vitro and in vivo studies were
performed. In contrast to previous reports, we found that
sorted CD133high and CD133dim LC-42 cells had equal
stemness gene expression profile, colony and sphere for-
mation capabilities in vitro and equal tumorigenic growth
pattern in NOD/SCID mice.
Results
Expression of stem cell related markers in the lung cancer
cell lines LC-42, HTB-182, EKVX and SELS
Based on the current knowledge on putative stem cell
markers, the cell line LC-42 and other three lung cancer
cell lines were phenotyped by flow cytometry and IHC. In
flowcytometry analysis, CD34 and CD45 were expressed
extremely low in these lung cancer cell lines (data not
shown), while the chemokine receptor CXCR4 was highly
expressed in the HTB-182 cell line, but not expressed in
the remaining cell lines. The CD117, CD31 and VEGFR
were weakly or negatively expressed in all lung cancer cell
lines. The epithelium specific marker Ber-EP4 was ex-
pressed heterogeneously in all the cell lines (Figure 1).
Interestingly, CD133, which has been suggested to be a
marker of tumor stem cells of different types of tumors,
was highly expressed (56.89±6.26%) in the LC-42 lung can-
cer cells, while the EKVX, SELS and HTB-182 cells showed
a weak expression of the CD133 antigen (0.39±0.30%, 0.43±
0.17% and 1.07±0.57%, respectively) (Table 1). In contrast,
the CD44 protein was strongly expressed in the EKVX,
SELS and HTB-182 cells (97.00±1.27%, 99.8±0.09% and
99.56±0.34%, respectively) while only 3.75±0.08% of the
LC-42 cells were CD44 positive (Table 1). The expression
of CD133 and CD44 in the 4 cell lines were further verified
by IHC. The IHC analysis of CD133 expression using the
clone AC133 (Figure 2A) showed consistent positive results
with the analysis done on FACS in the LC-42 cells, while
the other 3 lung cancer cell lines EKVX, SELS and HTB-
182 all had completely negative immunoreactivity for the
CD133 antibody. The expression of the antigen CD44 was
only positive in some single cells in the LC-42 cell line
while it was broadly expressed in the lung cancer cell lines
EKVX, SELS and HTB-182 (Figure 2B).
Expression of stem cell related transcription factors
OCT4, SOX2, SSEA1, and SSEA4 were analyzed on sec-
tions from the LC-42 and the other three lung cancer cell
lines. The staining of each one showed various immuno-
reactivity among the 4 lung cancer cell lines (Additional
file 1: Table S1). However, for the cell line LC-42, all these
transcriptfactors were found moderate or strong positive
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expressed. The pan-epithelial marker Ber-EP4 was widely
expressed in all the 4 cell lines (Figure 2A) (Table 2).
Colony and sphere formation of CD133 sorted LC-42 cells
When sorted CD133high and CD133dim LC-42 cells were
tested in a soft agar colony-forming assay no difference
in clononogenic capacity was found between the two cell
fractions at each cell seeding density, and a direct relation
between the number of cells seeded and number of col-
onies formed was seen in all experiments (Figure 3B).
When the sphere-forming assay was used, both sorted
CD133high and CD133dim cells had the capability to form
similar numbers of compact cell spheres in serum-free
medium (Figure 3A).
Expression of stemness genes in CD133high and CD133dim
LC-42 cells
The mRNA expression levels of Nanog, Oct4 and Sox2
genes, which are associated with maintenance of stemness,
were investigated in the CD133high and CD133dim cell
populations by relative quantitative real-time PCR analysis.
No significant differences of the gene expression levels
were found in the CD133high and CD133dim LC-42 cells
(Figure 3D). The epithelial marker E-Cadherin and mesen-
chymal marker N-Cadherin were also investigated in the
CD133high and CD133dim LC-42 cells, and both cell popu-
lations showed same expression levels of these genes.
Phenotype profile of LC-42 after cell sorting and culturing
FACS sorted CD133high and CD133dim LC-42 cells were
maintained in culture under the same culture condition
as for the parental unsorted LC-42 cells for three weeks.
Thereafter, expression of CD133 was examined. Interest-
ingly, the percentage of the CD133+ cells in both sorted
Figure 1 FACS analysis of CD133 antigen expression in the 4 different lung cancer cell lines. One representative experiment of the FACS
analysis of CD133 antigen expression in the 4 different lung cancer cell lines: LC-42, HTB-182, EKVX and SELS. CD133 antigen expression was
found to be strong in the cell line LC-42 (56.89±6.26%, n= 5), while were weakly expressed on the remaining cell lines and were similar to the
isotype control. The pan-epithelia marker Ber-EP4 was widely homogenous expressed in all the cell lines except EKVX.
Table 1 FACS analysis of the stem cell related markers in
the 4 lung cancer cell lines
Cell line marker LC-42 HTB-182 EKVX SELS
CD133 56.89±6.26 1.07±0.57 0.39±0.30 0.43± 0.17
CD44 3.75±0.08 99.56±0.34 97.00±1.27 99.8±0.09
CXCR4 0.44±0.37 13.10±6.42 0.13±0.03 0.33±0.12
Ber-EP4 99,03±0,61 99,74±0,21 48.22±2.70 92,87±0,43
CD117 1.47±0.72 0.47±0.35 0.49±0.16 0.13±0.05
CD31 0.50±0.08 0.74±0.72 0.53±0.25 0.12±0.03
VEGF R2 0.48±0.14 0.89±0.76 0.13±0.03 0.20±0.08
The values (mean±SD, n≥3) of stem cell markers on each lung cancer cell line
represent the average of at least three individual flow cytometry analyses.
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CD133high and CD133dim cell populations was identical
and reached the same level of CD133 expression as in
the parental unsorted LC-42 cells (Figure 3C), indicating
that both CD133high and CD133dim cell populations are
able to recapitulate the original CD133 heterogeneity
found in the parental unsorted LC-42 cells.
Characterization of SP cells in LC-42
SP cells have been suggested to contain tumor cells with
stemness properties [23]. When this was investigated in
the LC-42, the average SP cell fraction present in the
parental LC-42 cells was 0.91±0, 24% (mean±SD, n=8)
(Figure 4A). The SP cells and non-SP cells were sorted
and additional stemness gene analysis with the relative
quantitative real-time PCR method was performed. Com-
pared with the gene expression level in the parental un-
sorted LC-42 cells, the expression level of Nanog gene in
the SP cells was much higher than that in the non-SP cells
(ratio>5.0). The Sox2 gene expression level was equally
down-regulated in both the SP and non-SP populations
(ratio<0.5) (Figure 4C), while there was no significant dif-
ference for the Oct4 gene expression in the individual cell
populations studied.
When CD133 antigen expression was studied in LC-42
SP and non-SP, it was found that the percentages of the
CD133+ cells in the SP and non-SP fractions were 33.75%
and 42.19%, respectively. This confirmed that CD133+
cells were not enriched in the SP cells (Figure 5A).
Figure 2 IHC analysis of CD133, OCT4, SSEA1, SSEA4 and SOX2 in xenografts from different cell fractions. A. IHC analysis of CD133, and
the stem cell related transcription factors OCT4, SSEA1, SSEA4 and SOX2 in parental LC-42 cells, corresponding xenograft, and xenografts derived
from CD133high and CD133dim cells. The xenografts resemble their parental LC-42 cells for the expressions of CD133, OCT4, SSEA1, SSEA4 and
SOX2. B. IHC analysis of CD44 expression in 4 lung cancer cell lines LC-42, HTB-182, EKVX and SELS. All the representative images are at
40× magnifications.
Table 2 The summary of the IHC analysis in Figure 2
Marker material CD133 OCT4 SSEA1 SSEA4 SOX2 Ber-EP4
LC-42 cell line + + + + + +
LC-42 cells xenograft + + + + + +
CD133high cells xenograft + + + + + +
CD133dim cells xenograft + + + + + +
IHC analysis of CD133, and stem cell related transcription factors OCT4, SSEA1, SSEA4 and SOX2 in parental LC-42 cells, corresponding xenograft, and xenografts
derived from CD133high and CD133dim cells.
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Furthermore, distinct SP cells could be obtained in both
the CD133high and CD133dim fractions, with about 0.8%
and 0.86% respectively, which were similar to the SP per-
centage discovered in the parental unsorted LC-42 cells
(0.91±0.24%) (Figure 5B).
When sphere-forming analysis was performed, it was
found that SP cells showed capability to form spheres
even when cell seeding density was as low as 6500 cells
per well (Figure 4B). The early present cell spheres
began to attach to the bottom of the wells during the
second and the third week in the serum free medium.
From these cultured spheres, three patterns of colony
morphology, i.e. haloclone, meroclone and paraclones,
were generated (Figure 4B, a, b, c), while non-SP cells
were unable to form any cell sphere even with seeding
density at 1.0-1.5×105 cells per well. Single suspended
cells could be observed in the non-SP after 3 weeks cul-
ture (Figure 4B), but additional analyses showed that
these cells were apoptotic.
In vivo tumorigenesis assay
Both CD133high and CD133dim sorted LC-42 cells were
100% tumorigenic at every cell dose even when 1000
cells were inoculated in the animals. As expected from
the results of in vitro experiments, the time to tumor
formation was related to the number of cells xeno-
transplanted. Thus, when transplanting 1000 cells of sorted
CD133high and CD133dim LC-42 cells, six weeks was
needed to get tumours formed, while only 2 weeks was re-
quired when 1×106 cells were injected (Table 3). Altogether
our in vivo results showed no difference in tumour growth
between the CD133high cells and CD133dim LC-42 cells
(Figure 6A, B), indicating that the CD133 antigen express-
ing cells have no growth in vivo advantage when compared
to the CD133dim LC-42 cells. Furthermore, both CD133high
and CD133dim cells were able to generate tumors in the
second transplantation and no differences were seen in the
CD133high and CD133dim cell populations with regard to
both tumor size and tumor characterization.
The xenograft samples were embedded into paraffin
blocks and sections from these blocks were prepared for
additional IHC studies. A clear CD133 expression could
be immunohistochemically disclosed in all the xenografts,
including the xenografts from the sorted CD133high cells,
CD133dim cells and unsorted parental LC-42 cells, with
approximately the same intensity. Strong expressions of
OCT4, SOX2, SSEA1 and SSEA4 were seen in all the
xenograft samples (Figure 2A) (Table 2). In addition, the
pan-epithelial marker Ber-EP4 was strongly positive in all
the xenograft samples, verifying their epithelial cell origin.
Discussion
The cell surface marker CD133 has been associated with
tumor stem cells in lung cancer [20]. Following pheno-
typing of 4 human lung cancer cell lines, we found that only
the LC-42 cells expressed high levels of CD133. When the
LC-42 cell line was tested further both in vitro or in vivo,
we found that CD133 antigen expression in LC-42 cells was
not identifying cells with CSC/TIC properties.
Many investigators have attempted to identify and
isolate CSC/TIC using different surface markers. The
CD133, a surface glycoprotein linked to organ-specific
stem cells, has frequently been used to identify CSC/TIC
from fresh human tumour cells in brain [7], pancreatic
[11] and colon [9,10]. Purified CD133+ cells from these
types of cancers show self-renewal capacity and have
ability to form tumours in transplanted immunodefi-
ciency mice. The CD133 expressing cells from fresh
tumor samples were also found to have cancer-initiating
properties in both small cell and non-small cell lung
cancers. Furthermore, as few as 1000 CD133+ cells were
capable of inducing tumors in immunedeficient SCID or
nude mice [20]. CD133 antigen expression at various
levels was detected in various human cancer cell lines
[24,25]. In the liver cancer cell line Huh-7 and colon
cancer cell line Caco-2, the CD133 was expressed in
50% [24] and 70% [26] of the tumor cells respectively.
When CD133+ cells in some of these cell lines was fur-
ther investigated, it was found that CD133 expressing
tumor cells possessed high capacity for tumorigenicity.
Since our lung cancer cell line LC-42 had similar CD133
(See figure on previous page.)
Figure 3 In vitro analysis of the stemness properties in sorted CD133high and CD133dim LC-42 cells. A. Cell sphere-forming assay under
serum-free condition. 10% highest CD133+ cells and the lowest 10% CD133− were isolated via FACS. Spheres were generated from both sorted
CD133high and CD133dim LC-42 cell populations within 3 weeks. Representative cell sphere images were acquired at 40× magnification.
B. Colony-forming ability of different sorted LC-42 cell populations at different cell seeding numbers using soft agar clonogenic assay. The colony
numbers of each cell population were compared at different cell seeding numbers. A direct relation between the number of cells seeded and
number of colonies formed was observed. The clonogenic ability of different sorted cell populations showed no significant difference. The values
of colony numbers of each cell population represented the average of three individual analysis. C. Recapitulate phenotype of the original LC-42
cells by post-sorting cell culture. FACS analysis of CD133 just following sorting (column a) and at the third week after sorting under the
conventional cell culture condition (column b) showed the expressions of the CD133 in both CD133high and CD133dim cell fractions reached the
similar level as its original LC-42 cells at the third week after sorting. D. Relative quantitative real-time PCR analysis of the expression of stem cell
related genes Nanog, Oct4 and Sox2 in sorted CD133high and CD133dim LC-42 cell fractions. Real-time PCR assay revealed similar levels of these
genes expression in CD133high and CD133dim cell fractions. The error bar reflected the variation within the triplicates.
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Figure 4 SP and non-SP fractions in LC-42 lung cancer cells. A. One representative experiment of the side population in LC-42 cell line as
compared to the blocking control with verapamil. B. Sorted SP and non-SP cells were cultured in Defined Keratinocyte-SFM medium
supplemented with EGF and FGF, only SP cells have capability of forming spheres in serum-free medium (a). These spheres began to attach to
the bottom of the wells during the 2nd week under the same culture condition, three distinct patterns of colony morphologies, which were
holoclone (a), meroclone (b) and paraclones (c), could be easily identified. Non-SP cells were not able to form cell sphere. Representative colony
images were acquired at 40× magnification. C. Comparison of the expression pattern of stem cell related genes between SP and non-SP cells by
real-time PCR analysis, indicating similar levels of the expression of these genes in SP cells compared to non-SP cells. The error bar reflected the
variation within the triplicates. D. Colony-forming ability of sorted SP and non-SP LC-42 cells at different cell seeding numbers using soft agar
clonogenic assay. The numbers of colonies formed from each cell population were compared at different cell seeding numbers. The clonogenic
ability showed significant difference between SP and non-SP cells at lower cell seeding number of 10 cells per tube, showed no significant
difference at higher seeding density. The mean value reflected the average of three individual analyses.
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antigen expression as those cell lines, we decided to fur-
ther characterize the LC-42 human lung cancer cells.
In the present study, seven surface markers were used
to characterize the cell lines. Interestingly, we found a cor-
relation between the antigens CD133 and CD44 expres-
sion on the individual lung cancer cell lines tested. While
the LC-42 had high expression of CD133, no or weak ex-
pression of CD44 could be detected on the cell line. In
contrast, the cell lines HTB-182, EKVS and SELS all show
high expression of CD44 but weak or no expression of
CD133. These findings were also confirmed by immuno-
cytochemistry using the CD133 antigen clone AC133.
The differences observed in CD133 and CD44 expres-
sion cannot be explained by which type of primary lung
cancer the cell line originated from, since both the HTB-
182 and LC-42 were derived from squamous cell carcin-
oma while the EKVX and SELS cells were derived from
adenocarcinoma. Recently, it has been reported that
CD44 is a marker in lung cancer cell lines that define a
subpopulation of tumor initiating cells [27]. In our study,
no expression of CD133 was found in the cell lines
HTB-182, EKVS and SELS while all these cell lines were
highly positive for CD44 expression.
To investigate the role of CD133 in the LC-42 lung
cancer cells we characterized FACS sorted CD133high
and CD133dim cells both in vitro and in vivo. Transcrip-
tion factors OCT4, SSEA4, SSEA1 and SOX2 are related
to stemness properties [28]. Therefore, both IHC and
real-time PCR of LC-42 cells were performed to explore
the expression profiling of transcription factors. IHC stud-
ies showed that SSEA1 protein expression was strongly
positive in the LC-42 cell line, LC-42 xenografts, the
CD133high and the CD133dim xenografts. A weaker expres-
sion of OCT4, SSEA4 and SOX2 was seen by IHC, but
no difference was found in the various subtypes of LC-42
cells (Figure 2A), which is in line with the real-time PCR
analysis of Nanog, Oct4 and Sox2. As a physiological
process that occurs during various stages of embryogen-
esis, Epithelial-mesenchymal transition (EMT) program
has been reported also to play a crucial role during cancer
invasive growth and metastases [29]. EMT may facilitate
the cancer cells with the mesenchymal traits needed for
dissemination as well as self-renewal property for initiation
of secondary tumors and increasing evidence shows a
direct link between EMT and the CSCs [30]. In our study
there were no differences in the expression of N-Cadherin
and E-Caderin in the sorted CD133high and CD133dim LC-
42 cells, suggesting no EMT shift in these two different
cell populations.
In vitro colony and sphere formation assays were
performed to test whether there was any difference in
clonogenic growth among sorted CD133high and CD133dim
cells. Our results (Figure 3) show that both the CD133high
and CD133dim LC-42 cells exhibit equal growth potential
in vitro when examined with the 2D and 3D colonogenic
methods. If CD133high cells are the only population that
contains tumor initiating cells it would be expected that
CD133dim cells do not give rise to CD133high cells follow-
ing further culture. However, when sorted CD133high and
CD133dim cells were maintained in culture for 3 weeks, it
was found that both cell fractions were able to return to
the CD133 expression level of the parental LC-42 cells, in-
dicating that CD133high cells are not defining cells with
cancer stem cell properties.
It has been shown that cells with stem cell properties
from different types of normal tissues have a unique ability
to efflux Hoechst 33342 dye by an ATP-binding cassette
(See figure on previous page.)
Figure 5 The correlation between SP cells and CD133 antigen expression in LC-42 cell line. A. One representative experiment of the
CD133 antigen expression in the isolated SP and non-SP cells. The percentage of the CD133+ cells in LC-42 cell line is 51.27% (c): percentage of
CD133+ cells was 33.75% in SP (d) and 42.19% in non-SP (e), demonstrating no significant difference of the CD133 antigen expression between
SP and non-SP cells. B. One representative experiment of the SP in the isolated CD133high and CD133dim cells. A distinct SP was detected in both
isolated CD133high (b-1) and CD133dim (c-1) LC-42 cells, and no significant difference of the SP between CD133high and CD133dim cells. Cells with
added verapamil were used as the blocking control (b-2 and c-2).
Table 3 In vivo tumorigenicity assay of FACS sorted
CD133high and CD133dim LC-42 cells at different injected
cell doses in NOD/SCID mice
Group Cell type Number of the
cells injected
Number of the
mice with
tumor/ number of
the mice injected
Latency
No. injected
1 CD133high 1×103 3/3 6W
2 CD133dim 1×103 3/3 6W
3 CD133high 1×104 3/3 5W
4 CD133dim 1×104 3/3 5W
5 CD133high 1×105 5/5 3W
6 CD133dim 1×105 5/5 3W
7 CD133high 1×106 3/3 2W
8 CD133dim 1×106 3/3 2W
1 Unsorted cells 1×105 3/3 3W
2 Unsorted cells 2×105 3/3 3W
3 Unsorted cells 2×106 3/3 2W
4 Unsorted cells 5×106 6/6 2W
Comparison of xenograft formation in NOD/SCID mice with different numbers
of injected CD133high and CD133dim cells. Both FACS isolated CD133high and
CD133dim LC-42 cells were 100% tumorigenic in NOD/SCID mice at different
injected cell dose even only 1×103 cells were injected. Unsorted LC-42 cells
were established as control groups.
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(ABC) transporter [31]. These cell populations can be be
defined by flow as a side population (SP). Increasing evi-
dence indicates that cells in the SP fraction in different
human primary cancers as well as in cell lines contain
tumour-initiating cells [23,32-35]. This has also been found
in primary lung cancer [36]. The lung cancer cell line LC-
42 also displayed persistent SP cells representing around 1%
(0.91±0.24%) of the entire LC-42 cell population. Following
culturing in defined serum-free medium, SP cells had sig-
nificant higher cell sphere-forming potential compared with
non-SP cells. Furthermore, the transcription factor Nanog
was highly expressed in the SP fraction, suggesting that SP
cells in the LC-42 cell line may contain cells with greater
stemness properties. When we further studied the relation
between SP cells and CD133+ expression in the LC-42 cells,
no difference was found in the SP and non-SP cells for
CD133 expression, and in line with this no difference in the
colony formation assay between the CD133high SP and
CD133dim SP was seen (data not shown).
The gold standard used for identifying CSC is that the
candidate cell population must be able to initiate serially
xenograft tumors recapitulating the original tumor. In our
study, all animals showed tumor growth irrespectively
when unsorted, sorted CD133high and CD133dim cells
were injected and as few as 103 CD133high and CD133dim
cells were sufficient to form tumors in all animals. The
CD133high and CD133dim cells from the xenografts could
be serially transplanted without losing their ability to form
tumors. IHC staining of the xenografts derived from the
sorted CD133high and CD133dim cells showed no differ-
ence in stemness related gene expression, in comparison
to the parental LC-42 cells. In addition, both the
CD133high and CD133dim cells formed tumors, which were
similar to the tumors derived from the parental LC-42
cells. Furthermore, it was also observed that the tumors
derived from the CD133dim LC-42 cells were equally posi-
tive for the CD133 expression as in the tumors derived
from the CD133high cells and their parental LC-42 cells,
Figure 6 In vivo tumorigenicity assay of FACS sorted CD133high and CD133dim LC-42 cells in NOD/SCID mice. A. Comparison of xenograft
formation in NOD/SCID mice with different injected numbers of CD133high and CD133dim cells. Injected cell dose was found to be related with the
time of the bulk tumor appearance and tumour size. When 1000 cells were injected, both CD133high and CD133dim LC-42 cells formed tumors at the
5th week, while only 2 weeks was required when 1×106 cells were injected. B. Representative xenografts from the CD133high and CD133dim LC-42 cells
derived from the different injected cell doses. No significant difference of growth appeared between CD133high and CD133dim cells.
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further suggesting that both subpopulations contain simi-
lar numbers of cancer-initiating cells.
Recently Shmelkov et al. challenged the view that
CD133 is a marker of CSC/TIC in colon cancer. In their
study it was found that both CD133+ and CD133- anti-
gen expressing cells from metastatic colon cancers iso-
lated from liver were equally capable of initiating tumors
in mice [22]. Our results on the lung cancer cell line
LC-42 and CD133 antigen expression are in line with
Shmelkov’s observation. In contrast to the other lung
cancer cell lines studied, the LC-42 was also established
from a lymph node metastasis 3 months after the patient
had been treated with radiotherapy combined with
chemotherapy (Taxans).
In summary, we conclude that in the present study,
CD133 expression in the human lung cancer cell line
LC-42 does not determine in vitro as well as in vivo a
cell population with tumor initiating properties. There-
fore, other surface markers on lung cancer cells should
be explored in order to identify subpopulations of cells
with stemness properties.
Materials and methods
Human lung cancer cell lines and growth conditions
Four human lung cancer cell lines HTB-182, LC-42,
EKVX and SELS were used in the present study. Only
the HTB-182 cell line, which was established from a
sample of a lung mass taken from a patient with primary
lung squamous carcinoma, was purchased from ATCC
(American Type Culture Collection). All the other three
cell lines were established at the Department of Tumour
Biology in our hospital. The EKVX cell line was devel-
oped from a xenograft from a lung mass taken from a
patient with primary lung adenocarcinoma. Two cell
lines were established from lymph node metastasis of
lung cancer patients: The LC-42 cell line originated from
lung squamous carcinoma and the SELS cell line from
a lung adenocarcinoma. All cell lines were cultured in
standard coated flasks (Nunclon™Δ Surface; NUNC,
Denmark) at 37°C with 5% CO2, using RPMI-1640
medium (GIBCO, USA) supplemented with 10% Fetal
Bovine Serum ([FBS]; Sera-lab; Sussex, UK) and 2mM
Glutamine.
Phenotyping of lung cancer cell lines by flow cytometry
Prior to harvesting, the cell lines were grown until a
75% confluence. Following detachment of cells with
0.25% Trypin/EDTA (Lanzo, Belgium) and washing with
Dulbecco's phosphate-buffered saline (DPBS, Invitrogen,
USA), the cells were enumerated and transferred into
12×75 mm polystyrene round-bottom test tubes (BD
Falcon, USA) at a cell concentration of 1×106 cells/ml. A
staining buffer with gamma globulin at concentration of
1mg/ml (Gammagard, Baxter, UK) was added in order
to block FcR. Titrated amounts of phycoerythrin (PE)
conjugated mouse anti-human monoclonal antibodies
Ber-EP4, CD34, CD45, CD31, VEGFR2, CD117 and
CXCR4, or fluorescein isothiocyanate (FITC)-labelled
CD44 (all from BD Pharmingen, USA) and PE-labelled
CD133 (clone2/AC141 and clone1/AC133, Miltenyi Bio-
tech, Germany) were added to the test tubes and incu-
bated for 15–20 minutes on ice avoiding light exposure.
Excess antibody was removed by washing the cells twice
with DPBS. Five microliters (μl) of 7-AAD (BD Bio-
science, USA) was added into each sample to exclude
the dead cells before analysis by flow cytometry. Cells
stained with isotype-matched monoclonal antibodies (BD
Pharmingen, USA) served as negative controls. The cells
were analysed on a FACSCalibur™ and the CELL Quest
software (BD Bioscience, USA).
Immunohistochemistry
Cell blocks were prepared from each of the cell lines.
Following culturing of the cell lines into 80% confluence,
the cells were washed with DPBS, detached by 0.25%
Tripsin/EDTA (Sigma), harvested and centrifuged at 300g
for 5 minutes. The supernatant was carefully removed be-
fore 3 drops of plasma and 2 drops of thrombin were
added and mixed by tube rotation. After the mixture was
coagulated, 4% buffered formalin was added. The coagu-
lated mass was then placed in linen paper for further con-
ventional paraffin block preparation.
For immunocytochemistry (IHC), four-micrometer thick
sections from the above prepared blocks were dewaxed and
rehydrated in graded ethanol. To unmask epitopes, sections
were then microwaved in different optimised buffers for
different antibodies. Tris/EDTA buffer at pH 9.0 was used
for CD133 antibody; low pH 10 mM citrate buffer (pH =
6.0) was used for antibodies SOX2, SSEA1, SSEA4, OCT4
and Ber-EP4. To inhibit endogenous peroxidase, the sec-
tions were incubated with 3% hydrogen peroxide (Dako
Cytomation) at room temperature for 5 minutes. Thereafter
the primary antibodies were added onto the sections.
Sections with mouse anti-human CD133 (clone AC133/1
Miltenyi, 1:40 dilution), mouse anti-human SOX2, SSEA1,
SSEA4 and Ber-EP4 (R&D, 1:200, 1:100,1:100 and DAKO
1:200 dilution, respectively), and goat anti-human OCT4
(R&D, 1:100 dilution) were incubated overnight at 4°C.
The sections were then incubated with corresponding
secondary antibodies for 30 minutes at room temperature
and stained with 3,3'-diaminobenzidine tetrahydrochloride
(Dako EnVision™ + System Peroxidase (DAB), K4007,
DakoCytomation, CA, USA) before counterstained with
hematoxylin, dehydrated and mounted in Diatex. All sec-
tions were rinsed thoroughly with TBS-Tween wash buffer
(Dako Cytomation) after each incubation step. Sections
from a human seminoma specimen were used as positive
controls for antibodies OCT4, SSEA1 and SSEA4; Sections
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from a human gastrocarcinoma specimen were used as the
positive control for antibody SOX2; Sections from colon
cancer cell line CaCo-2 were used as the positive control
for CD133 antibody; Sections from human breast cancer
specimen were used as the positive control for antibody
Ber-EP4. Negative controls included substitution of the
antibodies with corresponding normal immunoglobulins of
the same concentration. All controls were satisfied before
experimental applications of the antibodies. Positivity was
scored as follows: low positivity (+) for 0–30% positive
cells; moderate positivity (++) for 30–70% positive cells;
and strong positivity (+++) for over 70% positive cells; no
immunoreactivity was scored as negative.
FACS cell sorting and side population assessment
Directly conjugated Phycoerythrin (PE)-labeled CD133
(clone2/AC141, Miltenyi Biotech) was added in saturated
amount and incubated for 30 minutes on ice avoiding light
exposure. The cells were thereafter washed twice in cold
RPMI-1640 medium. The IgG1-PE was used as isotype
control. Before sorting, the cells were filtered through a
40 μm cell-strainer cap (BD Falcon, USA) and then kept
on ice. The top 10% CD133+ cells and the lowest 10%
CD133- cells (defined as CD133high cells and CD133dim
cells, respectively, in the description) were gated and
sorted. Side population (SP) assay was performed by
Hoechst 33342 staining (Sigma-Aldrich, USA). Briefly,
cells were resuspended at 106 cells per milliliter in
RPMI1640 medium containing 2% FCS. The cells were
then incubated with 2.5 μg/ml Hoechst 33342 at 37°C for
90 minutes, which was found to be the optimal time point
in our studies (data not shown). To set the gate for SP
cells, Verapamil (Boehringer-Mannheim) was included at
50 μM together with the Hoechst dye in control sample.
In experiments where both SP and CD133 antigen profil-
ing were performed, CD133 antibody was added after the
Hoechst staining prior to flow cytomety analysis. Cell
sorting was performed on a FACSDiva cell sorter (Flow
Vantage machine, Becton Dickinson). The viabilities of
each subpopulation after sorting were checked using Try-
pan Blue (Sigma Chemical Co., St. Louis, MO).
Soft agar colony-forming assay
The colony-forming capability of the different subpopu-
lations derived from the LC-42 cells following sorting by
SP and CD133 antigen was evaluated in a soft agar assay
as described previously [37]. Briefly, soft agar cultures
were set up in triplicates in 10ml tubes by adding 0.2 ml
of August rat blood diluted 1:8, 0.2 ml of appropriately
diluted tumor cell suspensions, and 0.6 ml of 0.5% agar
(DIFCO Laboratories, Detroit, MI). After plating different
numbers of the sorted subpopulations of LC-42 cells in
triplicate, the tubes were incubated at 37°C in a low-
oxygen culture incubator. Following 3 weeks of incubation,
colonies containing more than 50 cells were recorded as
positive using an inverted microscope, and the number of
colonies were counted.
Sphere-forming analysis in serum-free medium
LC-42 cells were sorted into CD133high and CD133dim
subpopulations and SP and non-SP subpopulations. The
LC-42 CD133high and CD133dim cells were seeded at a
cell density of 300 cells/well in 6-well plates. SP and
non-SP cells were seeded at a density of 6500 cells/well
and 1.0×105 cells/well in 6-well plates, respectively. Cul-
ture condition consisted of Defined Keratinocyte-SFM
medium (Invitrogen, USA) complemented with EGF
20 ng/ml and FGF 10 ng/ml (Peprotech, USA). Sphere
morphology was observed and the numbers of spheres
were then counted.
RNA extraction and real-time PCR analysis
Sorted cells were collected and total RNA was extracted
from the sorted CD133high and CD133dim subpopula-
tions respectively by TRIzol reagent (Invitrogen USA)
according to the manufacturer's instructions, and subse-
quently reverse transcribed using the High Capacity
RNA-to-cDNA Kit (Applied Biosystems, USA). Fifty ng
of total RNA was used as template. Incubate conditions
were 16°C for 30 min, followed by 42°C 30 min, 85°C
5 min. Relative quantitative real-time analysis was per-
formed by the ABI 7500HT Real-Time PCR System (Ap-
plied Biosystems, USA). Thermal cycling conditions were
95°C for 10 min, followed by 40 cycles of 95°C 15s, 60°C
1min. All samples, including the no template controls,
were assayed in duplicate. PCR reaction without template
was served as negative control. The expression levels
were determined by TaqMan Gene Expression Assays (Ap-
plied Biosystems, USA) for the genes Nanog (assay ID
8S02387400_gl), Oct4 (assay ID Hs03005111_g1), Sox2
(assay ID Hs01053049_sl), E-Cadherin (assay ID Hs010
23895_m1) and the mesenchymal marker N-Cadherin
(assay ID Hs00169953_m1), The gene phosphoglycerate
kinase 1 (PGK1, assay ID Hs99999906_m1) was used as
endogenous control for normalization of gene expression,
and unsorted LC-42 cells were used for calibration. Data
were analyzed by the 7500 System Sequence Detection
Software, The Comparative CT method, which was ddCT,
was used to calculate relative transcripts levels.
Mouse xenograft studies
All animal experiments were approved by and performed
according to the guidelines set by the Animal Research
Ethics Board at University of Oslo. Four to five weeks old
non-obese diabetic/severe combined immunodeficiency
(NOD/SCID) male mice were used in all experiments. The
research was done in collaboration with the animal facility
in the Norwegian National Hospital. Different numbers of
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sorted CD133high and CD133dim LC-42 cells were mixed
with Matrigel (BD Biosciences, San Diego, CA) at a ratio
of 1:1 and injected subcutaneously into the right flank of
NOD/SCID mice at a maximum volume of 150 ul. Un-
sorted LC-42 cells were injected as positive control. The
animals were monitored twice a week and tumor size was
measured with callipers. Mice were sacrificed when the
size of the tumor reached a diameter of 1.5 cm. Tumor vol-
umes were determined using the formula: width2×length/2.
The paraffin blocks were prepared from the xenografts.
The expression of CD133 in the CD133high and CD133dim
xenografts were immunohistochemically examined in com-
parison to their original cell line LC42. The expression of
Ber-EP4, stemness transcription factors OCT4, SSEA1,
SSEA4, and SOX2 were also studied in the xenografts
immunohistochemically.
Additional file
Additional file 1: Table S1. IHC analysis of Ber-EP4, OCT4, SOX2, SSEA1
and SSEA4 in the lung cancer cell lines.
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